{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006767204,0.0009088516,0.001931957,0.002399624,0.0002084013,0.0009851636,0.0008751166,0.001013978,0.003541812],"category_scores_gemma":[0.0009819958,0.0002909772,0.0006017548,0.002257132,0.0004104078,0.001080005,0.0007754232,0.001858872,0.001155809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006616839,"about_ca_system_score_gemma":0.0009574449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001541525,"about_ca_topic_score_gemma":0.003536819,"domain_scores_codex":[0.9997869,0.00004355324,0.000035773,0.00003232361,0.00007680229,0.00002476676],"domain_scores_gemma":[0.9996655,0.0001819338,0.00005888785,0.000007706467,0.00005941229,0.00002656684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001350024,0.00006698688,0.0001042216,0.02259624,0.0001654534,0.0001403438,0.00003863789,0.000385366,0.001092793,0.002271991,0.02202445,0.9509786],"study_design_scores_gemma":[0.00009430505,0.0001581364,0.0006934064,0.008471993,0.0004427209,0.0009588999,0.00005440756,0.0001519404,0.0004877443,0.001736134,0.9867284,0.00002192408],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005737072,0.9993703,0.00003892804,0.0001090942,0.00008602891,0.00000266685,0.000009374323,0.000002510406,0.0003237922],"genre_scores_gemma":[0.0004396165,0.998989,0.0000625571,0.0001342859,0.00008559346,0.000002738562,0.00001608973,6.65057e-7,0.0002693653],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003541812,"threshold_uncertainty_score":0.01184851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1386676677073322,"score_gpt":0.4761857603569551,"score_spread":0.337518092649623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}